Project Grant R03CA308625
Award Date 6/15/26
Completion Date 5/31/28
Dollars Obligated $154K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Lexington, KY 40536, USA
Similar Awards
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded The University of Kentucky Research Foundation a Project Grant of $124,546 under the Cancer Research Manpower program (CFDA 93.398) to support cancer research training and investigation. The award, obligated on July 14, 2025, funds a two-year project (completion date June 30, 2027) titled "Enhancing TIL Efficacy in NSCLC Through Epigenetic Reprogramming and Computational Modeling." The project...
- Federal Grant Award Summary The University of Cincinnati received a $162,000 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) effective July 1, 2025, through June 30, 2027. This award funds research to develop and evaluate novel combination treatment strategies targeting colorectal cancer patients with KRAS mutations. The project specifically investigates the efficacy of combining KRAS inhibitors with HER3 (human epidermal...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a planning grant of $281,820 to the University of Kentucky Research Foundation under the Cancer Cause and Prevention Research program (CFDA 93.393) on July 1, 2026, with completion scheduled for June 30, 2029. This project grant supports the development and planning of a future intervention trial designed to improve clinical trial education and patient enrollment in cancer therapeutic studies. The planning phase will address...
- Federal Project Grant Award Summary Virginia Commonwealth University received a $634,062 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective June 5, 2026 through May 31, 2031. The grant supports fundamental cancer biology research examining atypical sphingolipids in hepatocellular carcinoma (HCC), a leading cause of cancer-related death. The research investigates how serine palmitoyltransferase (SPT) subunit SPTLC3...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant totaling $482,236 to Sloan-Kettering Institute for Cancer Research under the Cancer Treatment Research program (CFDA 93.395) on August 1, 2025, with a project completion date of July 31, 2030. This investigator-initiated Phase 2 clinical trial will evaluate the safety and efficacy of combining trastuzumab deruxtecan (T-DXD), an antibody-drug conjugate, with the anti-EGFR (epidermal growth factor receptor)...
- Federal Grant Award Summary The National Cancer Institute awarded a $164,484 Project Grant to The University of Kentucky Research Foundation on August 11, 2025, under the Cancer Cause and Prevention Research program (CFDA 93.393). This award supports a research initiative focused on developing and evaluating health communications targeting adults who smoke nondaily (ASN)—a population representing approximately one-third of current adult cigarette smokers in the United States yet demonstrating...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded $697,131 to Icahn School of Medicine at Mount Sinai under the Cancer Biology Research program (CFDA 93.396) to conduct a five-year research initiative examining immunosuppressive mechanisms in colorectal cancer (CRC). The project, which commenced May 1, 2026 and extends through April 30, 2031, will deliver fundamental research findings on how myeloid cells and cancer-associated fibroblasts interact to promote immune...
- Federal Project Grant Award Summary The National Cancer Institute awarded a $585,482 Project Grant under the Cancer Biology Research program (CFDA 93.396) to New York University School of Medicine for a five-year research initiative spanning June 1, 2026, through May 31, 2031. This award supports fundamental research investigating the role of the translation factor DAP5 in selective messenger RNA (mRNA) translation and m6A mRNA methylation as mechanisms driving breast cancer metastasis. The...
- Federal Grant Award Summary Deep Creek Pharma LLC received a $399,968 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) awarded on September 2, 2025, with completion scheduled for August 31, 2026. The awardee, in partnership with Wake Forest University Health Sciences, is developing TBAEFPREX, a novel nanoscale therapeutic agent designed to treat metastatic colorectal cancer (MCRC). TBAEFPREX is a modified thrombin-binding aptamer...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $157,980 to Loyola University of Chicago on August 8, 2025, under the Cancer Research Manpower program (CFDA 93.398) to support Dr. Jonathan Rennhack's research on colorectal cancer (CRC) metastasis. The project, which extends through July 31, 2028, focuses on unraveling the role of microenvironmental chemokines in beta-catenin/T-cell factor (TCF) signaling during CRC metastasis to the liver and lung. Dr. Rennhack...